Hirshberg Foundation for Pancreatic Cancer Research

Dedicated to advancing pancreatic cancer research and providing support to patients and their families.

Donate
  • ABOUT THE FOUNDATION
    • Agi’s Story
    • About Us →
      • Mission
      • Directors/Trustees
      • Scientific Advisory Board
      • How Our Journey Began
    • News →
      • Latest News
      • Research News
      • Foundation News
      • UCLA Activity Summary Reports
      • Newsletters
      • Press Room
    • Contact
  • PANCREATIC CANCER
    • About the Pancreas →
      • The Pancreas
      • Cancer Cells
      • Risk Factors
      • Symptoms
      • Diagnosis
      • Prognosis
      • Staging
      • Second Opinion
    • Treatment Options →
      • Surgery
      • Chemotherapy
      • Targeted Therapy
      • Radiation Therapy
      • Alternative Treatment Options
      • Clinical Trials
    • Supportive Care →
      • Obstructions
      • Pain Control
      • Nutrition
      • Cannabis
      • Palliative Care
    • Pancreatic Cancer Facts
    • Glossary of Terms
    • Frequently Asked Questions
  • RESEARCH
    • Seed Grant Program →
      • Seed Grant Recipients
      • Frequently Asked Questions
    • Seed Grant News
    • UCLA Program →
      • UCLA Center for Pancreatic Diseases
      • Basic Research
      • Translational Research
      • Sahin-Toth Laboratory
      • UCLA Pancreas Tissue Bank
      • UC Pancreatic Cancer Consortium
      • Simms/Mann Psychosocial →
        • Insights into Cancer
    • American Pancreatic Association
    • NIH Funded Projects
  • PATIENTS & CAREGIVERS
    • Patient Support
    • Where to Begin
    • Caregivers & Families
    • Symposium →
      • Symposium Presentations
    • Patient & Family Webinars
    • Genetic Counseling
    • Resources →
      • NCCN Guidelines for Patients
      • Patient Support Tools
      • Create Your Health Care Team
      • Patient Health Diaries
      • Support Groups
      • Financial Aid
  • HOW YOU CAN HELP
    • Planned Giving
    • Donor-Advised Funds
    • Event Calendar
    • Get Inspired
    • Fundraising Resources
    • November Awareness Month →
      • World Pancreatic Cancer Day
    • More Ways to Give →
      • You Can Help Funds
      • Host Your Own Event
      • Shop Online Store
      • Wedding Program
      • Volunteer
      • Car Program
  • SEARCH
Home / Research / Seed Grant Program / Seed Grant Recipients / Matteo Ligorio, MD, PhD

Matteo Ligorio, MD, PhD

Matteo Ligorio, MD, PhD
Matteo Ligorio, MD, PhD
Fellow
The General Hospital Corporation dba Massachusetts General Hospital
Discovering Novel Therapeutic Strategies for Patients with Pancreatic Cancer

Overview

Pancreatic cancer (PDAC) lethality is linked to a combination of intrinsic chemoresistance, rapid tumor growth, and high metastatic propensity. Tumor stroma consists of a complex ecosystem composed of immune cells, endothelial cells, and cancer associated fibroblasts (CAFs), providing a niche for cancer cells to modulate tumor growth and invasive behavior. Pancreatic CAFs make up the bulk of the tumor stroma, which have classically been thought to increase growth, suppress the immune response, and enhance metastatic dissemination. We find that tumor stroma promotes an aggressive phenotype with the concomitant ability to proliferate and metastasize, which we termed the double positive (DP) phenotype. We showed that this phenotype positive correlates with patient worsened survival and chemoresistance. Furthermore, we discovered that the DP phenotype is linked to the co-activation of two important cellular pathways (MAPK and STAT3) at single cell level, which makes these cells potentially vulnerable to the simultaneous inhibition of these two pathways. Therefore, we plan to develop strategies to therapeutically target DP cells by using a combination of the latest genome-editing technology (CRISPR) and with existing small molecule inhibitors of these pathways (trametinib and pyrimethamine). Moreover, we propose to better define the role of the DP phenotype in PDAC chemoresistance (primary vs. acquired chemoresistance). By obtaining pre and post treatment biopsies from patients who respond vs. patients who do not respond to preoperative chemotherapy, we will determine how these DP cells contribute to chemoresistance. This work will provide new insight into PDAC behavior and open novel therapeutic avenues.

Research

  • Seed Grant Program
    • Seed Grant Recipients
      • Katelyn T. Byrne, PhD
      • Julienne L. Carstens, PhD
      • Alicia K. Fleming Martinez, PhD
      • Mark Girgis, MD
      • Conan Kinsey, MD, PhD
      • Jacques Lux, PhD
      • Jimin Min, PhD
      • Somnath Pandey, PhD
      • Fredrik Ivar Thege, PhD
      • Liying Zhang, MD, PhD
  • Seed Grant News
  • UCLA Program
    • UCLA Center for Pancreatic Diseases
    • Basic Research
    • Translational Research
    • Sahin-Toth Laboratory
    • UCLA Pancreas Tissue Bank
    • UC Pancreatic Cancer Consortium
    • Psychosocial Care via Simms/Mann
      • Insights into Cancer
  • American Pancreatic Association (APA)
  • NIH Funded Projects

Patient Support Resources

from the comfort of your home


Our Webinar Library »

Never Give Up.
The journey continues with an end in sight.
Our Stories »
SUBSCRIBE
Our Free E-Newsletter
Sign up to receive information on breaking news, patient programs and upcoming events.
You can custom tailor your subscriptions and unsubscribe at any time.
  • How You Can Help
  • Make A Donation
  • Host an Event
  • Shop Online Store
  • Signature Events
  • L.A. Cancer Challenge
  • Tour De Pier
  • Hirshberg Training Team
  • More
  • News
  • Press
  • Contact

Stay Connected

Join Our E-newsletter

  • Legal and Privacy
  • Financial Information
  • Contact